BioWorld
-
Iterum in a $52M private placement from investors
-
Novo's Ozempic gets FDA go-ahead to expand label for reducing MACE
-
Bionetix secures $9.33M in series B funding for AML/MDS and glaucoma treatment
-
Oncogene Ras affects memory consolidation
-
Bench Press for Jan. 17, 2020
-
Holiday notice
-
Biontech acquires Neon in $67M all-stock deal to strengthen T-cell portfolio
-
Frazier Healthcare closes Life Sciences X with more than $617M
-
Industry: Trade agreement important first step toward fairer Chinese market
BioWorld MedTech
-
Australia amends first tranche of broad medical device regulations
-
Embolization coils show well in study of LAA leaks, but questions abound
-
M&As and deals up overall in 2019 for med tech, an investor haven in 2020
-
Oviva raises $21M to advance diabetes treatment program in Europe
-
Mexican company moves to 3D scanning and printing for orthotic devices
-
BioWorld MedTech’s Neurology Extra for Jan. 17, 2020
-
Holiday notice
-
Wall Street wonders where Exact Sciences is headed in wake of Genomic Health acquisition
-
Mojo Vision’s smart contact lens wins breakthrough device designation from FDA
BioWorld Asia
-
China's financing activity slows as partnering grows, Chinabio say
-
Gennbio licenses in two immunosuppressants valued up to $164M from Genexine
-
Innovent scores first IND for TIGIT antibody and explores PD-1/RNAi combination
-
Transcenta closes $100M series B+ to advance pipeline and IPO plan
-
Boehringer inks $1B+ antifibrosis deal with Singapore's Enleofen Bio
-
Adagene raises $69M series D to advance lead immuno-oncology programs
-
Targovax scores potential $100M KRAS vaccine deal in China
-
As bushfires continue to burn, Australia’s regulators don’t anticipate delays
-
Genesen secures $1.9M for peptide-based autoimmune disease treatment
